AlphAIAlphAI — Financial news for AI agents
BenzingaNOV 242 min read$IVVD

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness - Invivyd (NASDAQ:IVVD)

Antiviral potency 1.5-fold greater on average than nirsevimab and 1.2-fold greater on average than clesrovimab against established authentic RSV strains representing circulating variants

Original reporting
Benzinga · Globe Newswire
Published Nov 24, 2025, 12:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 24, 2025, 12:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IVVD
Bullish
high confidence
Mentioned
$IVVD
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$IVVDBullishMed
01

Why it matters

The announcement signals progress in RSV therapeutics, which could boost investor confidence and positively influence IVVD stock valuation.

02

Market read

The news is relevant for biotech investors, especially those focused on antiviral and respiratory disease therapeutics.

03

What to watch

Potential delays in IND readiness or regulatory hurdles could negate the initial positive sentiment.

Relevance 6/10Timing: Immediate, as the news was published on 2025-11-24

Background

Invivyd is advancing its RSV antibody candidate VBY329, targeting 2H 2026 for IND readiness, indicating ongoing development efforts in antiviral therapeutics.

Company-level read

Ticker impact

$IVVDBullishHigh confidence
Context

The news pertains to Invivyd's development of a promising RSV antibody candidate, which could influence investor sentiment and valuation.

Expected impact

Moderate upward movement in IVVD stock price over the short to medium term.

Evidence & confidence

The news highlights a significant advancement in Invivyd's pipeline with promising antiviral potency, which is likely to be viewed favorably by investors, especially given the company's focus on RSV therapeutics.

Market effects

Sector

Potential positive impact on biotech and pharmaceutical sectors focused on antiviral therapies.

Regional

Limited regional impact, primarily affecting US-based biotech stocks.

Global

Moderate, as RSV therapeutics have global relevance, but the impact is company-specific.

Counterpoint

What could challenge this read

The positive news may already be priced in, and subsequent clinical setbacks could lead to a sharp decline.

Key entities

  • Company
    Invivyd

    Biotech firm focused on antiviral therapeutics.

  • Drug Candidate
    VBY329

    Potential best-in-class RSV antibody candidate.

Read at source← All news

Related articles

OCT 14
$IVVDMedAI 8/10

Invivyd launches phase 2 trial of VYD2311 for long COVID

Invivyd (NASDAQ:IVVD) initiated a Phase 2 trial of VYD2311 for Long COVID and Post-Vaccination Syndrome. The trial will enroll 130 participants and assess safety, tolerability, and efficacy over 90 days. VYD2311 has shown in vitro potency against SARS-CoV-2 variants. Initial data is expected in mid-2027. The trial is part of Invivyd’s broader REVOLUTION clinical program.

investing.com1 min
OCT 14
$IVVDMedAI 8/10

Invivyd, Inc. (IVVD) Begins Phase 2 Trial of VYD2311 for Long COVID/PVS

Invivyd, Inc. (IVVD) has initiated a Phase 2 trial, FLINTLOCK, to evaluate the safety and efficacy of VYD2311, a monoclonal antibody, in treating Long COVID and Post-Vaccination Syndrome. The trial involves ~130 participants and will assess high-dose VYD2311 against a placebo over 90 days. VYD2311 has shown strong antiviral potency against SARS-CoV-2 variants. Success could open a new treatment market, addressing a significant unmet need.

tradingview.com1 min
OCT 14
$IVVDMedAI 8/10

Millions live with long COVID. A trial will test an antibody as a possible treatment.

Invivyd (IVVD) and the SPEAR Study Group initiated the FLINTLOCK Phase 2 trial to test the monoclonal antibody VYD2311 for treating Long COVID and Post-Vaccination Syndrome. The trial will evaluate safety, efficacy, and pharmacokinetics over 90 days. VYD2311 has shown antiviral potency against all SARS-CoV-2 variants tested. Initial data is expected in mid-2027.

stocktitan.net2 min
SEP 29
$IVVDMedAI 9/10

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine…

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 • VYD2311 met all primary and secondary endpoints comparing

SEC EDGAR 8-K2 min
SEP 29
$IVVDMedAI 8/10

Invivyd Reports VYD2311 Meets Primary Safety Endpoints In Phase 3 Trial

Invivyd (IVVD) reported that its COVID-19 monoclonal antibody VYD2311 met primary safety endpoints in the Phase 3 LIBERTY study, showing favorable safety and tolerability compared to an mRNA vaccine. The study enrolled 210 healthy adults, with 56.5% of VYD2311 recipients experiencing adverse events versus 91.4% for the vaccine. The company plans to use the data to support a BLA submission to the FDA. IVVD stock closed at $0.95, up 1.69%, and is trading at $0.99 in pre-market.

rttnews.com2 min
AUG 13
$IVVDMed

Invivyd Reports Second Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollme

SEC EDGAR 8-K6 min